{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-034427","form_type":"8-K","ticker":"PYXS","cik":"0001782223","company_name":"Pyxis Oncology, Inc.","filed_at":"2024-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.511362+00:00","generated_at":"2026-06-04T10:15:43.255279+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Pyxis Oncology reports FY2023 net loss of $73.8M, advances PYX-201 and PYX-106 trials","bullets":["Net loss of $73.8M ($1.85/share) vs $120.7M ($3.65/share) in FY2022; R&D expenses fell to $49.6M from $86.1M.","Cash, equivalents, and short-term investments $120.8M as of Dec 31, 2023; post-period raised $50M PIPE and $10.8M ATM, extending runway into 2H 2026.","PYX-201 Phase 1: 37 patients dosed; cleared DLT for Cohort 6; escalating to Cohort 7 at 8 mg/kg; initial data expected fall 2024.","PYX-106 Phase 1: 21 patients dosed; Cohort 5 fully enrolled at 8 mg/kg Q2W; preliminary data expected 2H 2024.","Feb 2024 PIPE investors include Deep Track Capital, Ridgeback, Blue Owl, Laurion Capital, StemPoint Capital."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-034427","json":"https://secwatch.observer/filing/0000950170-24-034427.json","markdown":"https://secwatch.observer/filing/0000950170-24-034427.md","text":"https://secwatch.observer/filing/0000950170-24-034427.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782223/000095017024034427/0000950170-24-034427-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782223/000095017024034427/pyxs-20240321.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T10:15:43.255279+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3d91a738a72172b7334ef54043510ce843365eac","claim":"Pyxis Oncology, Inc. reported the full year ended December 31, 2023 results: net income $73.8 million, or ($1.85) per common share.","evidence_excerpt":"Net loss was $73.8 million, or ($1.85) per common share, for the year ended December 31, 2023, compared to $120.7 million, or ($3.65) per common share, for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782223/000095017024034427/0000950170-24-034427-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2023"},{"label":"Net income","value":"$73.8 million, or ($1.85) per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}